Theravance Biopharma (FRA:0TB) ROCE %: -5.87% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:0TB Theravance Biopharma Inc FRA:0TB
72 GF Score
Price €14.60
GF Value €16.18
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Theravance Biopharma ROCE %?

Theravance Biopharma FRA:0TB -0.68% 72 ROCE % is -5.87% as of Mar. 2026. GuruFocus rates FRA:0TB with a GF Score™ of 72/100 and a GF Value™ of €16.18 (Modestly Undervalued). The stock has 3 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Theravance Biopharma's annualized ROCE % for the quarter that ended in Mar. 2026 was -5.87%.

Theravance Biopharma  (FRA:0TB) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Theravance Biopharma ROCE % Related Terms

Theravance Biopharma ROCE % Historical Data

* Premium members only.

The historical data trend for Theravance Biopharma's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Theravance Biopharma ROCE % Chart

Theravance Biopharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -80.57 -19.76 -9.85 -12.65 32.62

Theravance Biopharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -16.75 83.90 -2.45 71.47 -5.87
FRA:0TB
72GF Score
Theravance Biopharma Inc FRA:0TB
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Theravance Biopharma ROCE % Calculation

Theravance Biopharma's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=112.479/( ( (338.224 - 30.641) + (414.677 - 32.71) )/ 2 )
=112.479/( (307.583+381.967)/ 2 )
=112.479/344.775
=32.62 %

Theravance Biopharma's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=-22.388/( ( (414.677 - 32.71) + (408.551 - 27.485) )/ 2 )
=-22.388/( ( 381.967 + 381.066 )/ 2 )
=-22.388/381.5165
=-5.87 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -5.87% mean?
Theravance Biopharma (FRA:0TB) has a ROCE % of -5.87% as of Mar. 2026.
Is Theravance Biopharma's ROCE % too high?
Theravance Biopharma's current ROCE % is -5.87%. Overall, Theravance Biopharma has a GF Score™ of 72/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Theravance Biopharma's ROCE % compare to ABUS and SANA?
Theravance Biopharma's ROCE % of -5.87% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Theravance Biopharma's current ROCE % is -5.87%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Theravance Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Theravance Biopharma (FRA:0TB) is currently considered Modestly Undervalued. The stock's GF Value™ is €16.18, compared to a current price of €14.60 — trading 9.8% below its estimated fair value. The current ROCE % is -5.87%. Theravance Biopharma's overall GF Score™ is 72/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Theravance Biopharma (FRA:0TB), the current ROCE % is -5.87% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Theravance Biopharma (FRA:0TB) Overvalued in 2026?

Based on GuruFocus' analysis, Theravance Biopharma stock appears to be undervalued. The current stock price of €14.60 is trading 9.8% below its estimated GF Value™ of €16.18. GuruFocus considers Theravance Biopharma to be Modestly Undervalued.

Key valuation signals for FRA:0TB:

  • ROCE %: -5.87%
  • GF Value™: €16.18 vs. price of €14.60 (9.8% below fair value)
  • GF Score™: 72/100 with 3 warning signs

No single metric tells the full story. See the FRA:0TB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Theravance Biopharma Business Description

Other Exchanges TBPH:USA
Address C/O Theravance Biopharma US, LLC, 901 Gateway Boulevard, South San Francisco, CA, USA, 94080
Theravance Biopharma Inc is a biopharmaceutical company focused on the development and commercialization of medicines to improve patients lives. The company leverages decades of expertise and has developed FDA-approved YUPELRI (revefenacin) inhalation solution for the maintenance treatment of patients with COPD. Its ampreloxetine Phase 3 clinical study (CYPRESS) for the treatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy did not meet its primary endpoint. The company operates in a single segment, the development and commercialization of human therapeutics, and operates in the United States, which generates maximum revenue, and Europe.
72GF Score

Get the complete analysis for FRA:0TB

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€14.60
Price
€16.18
GF Value